BioSpace News Archive

Treadwell Therapeutics, today announced a presentation for the Company’s CFI-402411 program, an oral, first-in-class inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) a negative regulator of immune cell activation, at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Abbott (NYSE: ABT) today announced new, late-breaking data from the global Leadless II IDE study evaluating Abbott’s investigational Aveir leadless pacemaker in patients with certain abnormal heart rhythms.

Nxt-ID, Inc., provider of personal emergency response systems, health communications devices and IoT technology, announced financial and operations results for the third quarter and nine-month period ended September 30, 2021.

Actym Therapeutics today announced that ACTM-838 has been selected as a lead clinical development candidate for the treatment of solid tumors.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material that makes up its CypCaps™ pancreatic cancer product does not cause skin irritation.

InterVenn Biosciences, the leader in glycoproteomics, presented results today on a predictive signature capable of identifying non-small cell lung cancer patients that will benefit most from immune checkpoint inhibitors

Rapid Therapeutics Science Laboratories (OTC: RTSL) (“Rapid Therapeutic’’ or the “Company”), announces today that Chief Executive Officer Donal Schmidt will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021.

InterVenn Biosciences requests that their press release NewsItemId: 20211112005301 “InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of Cancer” be killed.

Aimmune Therapeutics, Inc., today presented results from longitudinal analyses evaluating immunological outcomes of long-term daily oral immunotherapy (OIT) with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp].

HydroCision Inc., a medical device company that pioneered high velocity, heat-free, FluidJet™ technology for surgical resection, congratulates PROCEPT BioRobotics on the recent closing of its upsized initial public offering.